AstraZeneca will spend €65 million on biologic production, research, and development in Athlone and Blanchardstown.
Alexion, AstraZeneca’s Rare Disease group recently announced that a €65 million investment was made across its campuses in College Park, Blanchardstown, and Monksland Industrial Park, Athlone, in new and improved capabilities.
The three investments that will be the focus of the investment program are the installation of new machinery for making drug substances, the building of a Manufacturing Sciences & Technology Lab in College Park, and the construction of warehousing facilities to support ambient and cold storage at both sites in College Park and Athlone.
The facilities at each site’s storage will enable Alexion to produce more drug substances in Ireland. Scaling up the production of biologic therapeutic substances in Ireland will be made possible by the Alexion Manufacturing Sciences & Technology Lab in College Park.
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. Since it has been a leader in treating rare diseases for almost 30 years, Alexion is committed to helping patients and their families with rare diseases by finding, developing, and selling life-altering medications. Alexion concentrates its development efforts on haematology, nephrology, neurology, metabolic diseases, cardiology, and ophthalmology while concentrating its research efforts on novel molecules and targets in the complement cascade.
AstraZeneca is a large, scientifically-driven biopharmaceutical firm with a focus on the research, development, and commercialisation of prescription drugs for oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, respiratory & immunology, and oncology.